Tag: Gepirone

First approved in 1986, the Azapirone buspirone was a significant development in psychotherapeutic drug therapy, offering a new path for treating anxiety. Unlike benzodiazepines, which are often associated with sedation and dependence, understanding what class of drugs are Azapirones reveals a distinct approach that primarily targets serotonin receptors to manage symptoms.

Following a lengthy and controversial development process, the FDA approved gepirone extended-release (Exxua) in September 2023 for major depressive disorder. While both gepirone and buspirone (Buspar) belong to the same azapirone class of medications, there are several key distinctions in **how is gepirone different from buspirone?**.

Approved by the FDA in 2023 after a multi-decade journey, gepirone (marketed as Exxua) offers a new treatment option for adults with major depressive disorder (MDD). Discover what class of medication is gepirone and how its novel mechanism of action sets it apart from more traditional antidepressants.

In 2025, the U.S. Food and Drug Administration (FDA) expanded the approval for Spravato (esketamine), making it a new standalone monotherapy option for adults with treatment-resistant depression. There is no single answer to "what is the newest and best antidepressant?" because the most effective treatment depends on individual patient factors. Several novel medications have recently hit the market, targeting different mechanisms than traditional antidepressants.

Gepirone, recently approved by the FDA for treating major depressive disorder (MDD) in adults, operates with a unique pharmacological approach compared to many other antidepressants. As a member of the azapirone class, **what is the mechanism of action of gepirone** involves the selective modulation of serotonergic activity in the brain, offering a novel treatment option for mood disorders.

In September 2023, the U.S. Food and Drug Administration (FDA) approved Exxua (gepirone extended-release) for the treatment of major depressive disorder (MDD) in adults. This marked a significant milestone, introducing a novel class of oral antidepressants into the market that functions differently than many existing options like selective serotonin reuptake inhibitors (SSRIs).